Jerry Mendell, in PPMD Webinar, Details Plans for Possible Trial of Duchenne Gene Therapy – Muscular Dystrophy News
Muscular Dystrophy News |
Jerry Mendell, in PPMD Webinar, Details Plans for Possible Trial of Duchenne Gene Therapy
Muscular Dystrophy News In a recent webinar, Dr. Jerry Mendell with Nationwide Children’s Hospital rolled out plans for a Phase 1/2a clinical trial of a new gene therapy for Duchenne’s muscular dystrophy (DMD). Final go-ahead for the trial awaits U.S. Food and Drug … |
ChronicleLive |
Newcastle firm uses seaweed to transport stem cells in ground breaking new system
ChronicleLive Atelerix’s new system makes it simpler to transport cells used in stem cell therapy, and allows them to be delivered in a ready to use format. Scientific founder, professor Che Connon of Newcastle University, has been working on the technology for five … Atelerix stems from Newcastle researchGlobal University Venturing |
PLoS Blogs (blog) |
Gene Therapy and September Scenes
PLoS Blogs (blog) Today I’m giving an invited lecture at Georgia College, “Gene Therapy: A Forever Fix”? I’ve given the talk many times, since my book The Forever Fix was published in 2012, but this is the first time I won’t cry. That’s because the first children who … |
|
OncBioMune Meets Primary Objective in Trial of ProscaVax Immunotherapy Vaccine for Prostate Cancer
Nasdaq ProscaVax is OncBioMune’s novel immunotherapeutic cancer vaccine consisting of a combination of prostate cancer associated PSA with the biological adjuvants interleukin-2 (IL-2) and granulocyte-macrophage colony-stimulating factor (GM-CSF). The study … |
|
OncBioMune Meets Primary Objective in Trial of ProscaVax Immunotherapy Vaccine for Prostate Cancer
Nasdaq ProscaVax is OncBioMune’s novel immunotherapeutic cancer vaccine consisting of a combination of prostate cancer associated PSA with the biological adjuvants interleukin-2 (IL-2) and granulocyte-macrophage colony-stimulating factor (GM-CSF). The study … |